Volume 19 Issue 6
Jun.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(6): 894-897
XUE Lu-xin, LI Xiao-yang, WANG Jing. Clinical characteristics and risk factors of heart failure patients after hematopoietic stem cell transplantation treatment[J]. Chinese Journal of General Practice, 2021, 19(6): 894-897. doi: 10.16766/j.cnki.issn.1674-4152.001943
Citation: XUE Lu-xin, LI Xiao-yang, WANG Jing. Clinical characteristics and risk factors of heart failure patients after hematopoietic stem cell transplantation treatment[J]. Chinese Journal of General Practice, 2021, 19(6): 894-897. doi: 10.16766/j.cnki.issn.1674-4152.001943
shu

Clinical characteristics and risk factors of heart failure patients after hematopoietic stem cell transplantation treatment

doi: 10.16766/j.cnki.issn.1674-4152.001943
  • 1.

    Department of Pharmacy, Ruijin Hospital, Shanghai 200025, China

Funds:

 81500162

  • Received Date: 2020-11-13
    Available Online: 2022-02-16
    Abstract
  •   Objective  To explore the clinical characteristics and risk factors of patient with heart failure after haematopoietic stem cell transplantation(HSCT), improve methods for the early recognition and intervention for patients with heart failure after haematopoietic stem cell transplantation and improve the prognoses of patients.  Methods  From July 2017 to July 2019, a total of 200 cases of bone marrow and peripheral blood stem cell transplantation were obtained. On the basis of the N terminal value of b-type natriuretic peptide precursor (NT-proBNP) and heart failure symptoms, patients were divided into the heart failure group (patients with symptoms of heart failure and the NT-proBNP>125 pg/mL) and heart failure group, and clinical features and possible risk factors of the patients in the two groups were compared.  Results  The incidence rate of heart failure after HSCT was 22.50%. The haematopoietic stem cell transplantation group before transplantation in patients with heart failure in the aftermath of the NT-proBNP value, pulmonary infection, cord blood combined rate of peripheral blood haematopoietic stem cell transplantation, not in all matches, whether for recurrence of the pretreatment of refractory, cyclophosphamide or anthracycline-based combined with cyclophosphamide solution rate and spore. The anti-thymocyte immunoglobulin+ring anti-rejection scheme selection rate was higher, and haemoglobin value of the haematopoietic stem cell transplantation group was lower than those of the heart failure group, the difference statistically significant (all P < 0.05); Logistic regression analysis showed a high NT-proBNP value before transplantation and high NT-proBNP value one month after transplantation, combined with pulmonary infection and umbilical cord blood combined with haematopoietic stem cell transplantation were independent risk factors for heart failure after hematopoietic stem cell transplantation (OR=1.184, 1.154, 1.091, 0.217).  Conclusion  High NT-proBNP value before transplantation, high NT-proBNP value one month after transplantation, combined with pulmonary infection and umbilical cord blood combined with peripheral blood haematopoietic stem cell transplantation are independent risk factors for heart failure after haematopoietic stem cell transplantation. Special attention should be given to such patients in clinical practice for early intervention, reduction of the risk of heart failure and improvement of prognosis.

     

    • FullText(HTML)
  • loading
    • References(21)
  • [1]
    曹琳琳, 丁凯阳, 宋浩, 等. 自体造血干细胞移植治疗恶性淋巴瘤的疗效及影响因素[J]. 中国组织工程研究, 2021, 25(13): 1993-1998. doi: 10.3969/j.issn.2095-4344.3510
    [2]
    张文坚, 马灵甫, 王志敏, 等. 异基因造血干细胞移植患者的四肢肌肉量及影响因素调查[J]. 中国组织工程研究, 2021, 25(13): 1999-2004. doi: 10.3969/j.issn.2095-4344.2197
    [3]
    史楠, 田金满, 张勃, 等. 积极心理护理干预对造血干细胞移植患者极期焦虑的影响[J]. 河北医科大学学报, 2020, 41(10): 1216-1220. doi: 10.3969/j.issn.1007-3205.2020.10.022
    [4]
    赵鹏, 张燕, 李艳菊, 等. 异基因造血干细胞移植治疗淋巴瘤合并HLH预处理方案的研究[J]. 重庆医学, 2020, 49(15): 2491-2494. doi: 10.3969/j.issn.1671-8348.2020.15.018
    [5]
    肖方, 刘强, 郭欢绪, 等. 异基因造血干细胞移植治疗成人Ph染色体阳性急性淋巴细胞白血病的临床疗效[J]. 现代肿瘤医学, 2020, 28(19): 3406-3409. doi: 10.3969/j.issn.1672-4992.2020.19.028
    [6]
    朱成琳, 陈广华, 翟宗, 等. 儿童异基因造血干细胞移植术后巨细胞病毒感染临床分析[J]. 临床儿科杂志, 2020, 38(9): 641-646. doi: 10.3969/j.issn.1000-3606.2020.09.001
    [7]
    黄育玲, 王翠连, 刘燕珍, 等. 造血干细胞移植极期运用Orem自理模式的临床效果[J]. 护理实践与研究, 2020, 17(16): 57-59. doi: 10.3969/j.issn.1672-9676.2020.16.021
    [8]
    杨杰孚, 王华, 柴坷. 2018中国心力衰竭诊断和治疗指南亮点[J]. 中国心血管病研究, 2018, 16(12): 1057-1060. doi: 10.3969/j.issn.1672-5301.2018.12.001
    [9]
    张素平, 孙玲, 万鼎铭, 等. 非血缘外周血造血干细胞移植治疗重型再生障碍性贫血的有效性[J]. 中国组织工程研究, 2020, 24(31): 4994-5001. doi: 10.3969/j.issn.2095-4344.2130
    [10]
    冯术青, 薛慧, 王翠民, 等. 亲缘间单倍体相合外周血造血干细胞移植预处理方案治疗重型再生障碍性贫血26例分析[J]. 解放军医学杂志, 2020, 45(9): 962-966. https://www.cnki.com.cn/Article/CJFDTOTAL-JFJY202009010.htm
    [11]
    LIU Y B, YUAN W, LI M, et al. In situ buccal carcinoma in a teenager after hematopoietic stem cell transplantation: a case report[J]. Medicine, 2020, 99(43): e22781. doi: 10.1097/MD.0000000000022781
    [12]
    李勇, 施圆圆, 朱国庆, 等. 未成熟血小板比率在异基因造血干细胞移植预测血小板植入中的价值[J]. 检验医学, 2020, 35(7): 651-654. https://www.cnki.com.cn/Article/CJFDTOTAL-SHYY202007006.htm
    [13]
    章建丽, 金爱云, 庞卫林. 1例造血干细胞移植病人预处理期并发三度房室传导阻滞的护理[J]. 全科护理, 2017, 15(21): 2687-2688. doi: 10.3969/j.issn.1674-4748.2017.21.061
    [14]
    孙爱华, 伍满群, 张诚, 等. 36例学龄前儿童造血干细胞移植极期的临床观察与护理[J]. 中国输血杂志, 2016, 29(10): 1110-1113. https://www.cnki.com.cn/Article/CJFDTOTAL-BLOO201610011.htm
    [15]
    徐萌, 张蓓, 贾滟文. 预见性护理干预对骨髓增生异常综合征异基因造血干细胞移植的影响[J]. 齐鲁护理杂志, 2020, 26(17): 42-44. doi: 10.3969/j.issn.1006-7256.2020.17.012
    [16]
    徐亮, 杨松, 王稳, 等. NT-proBNP对慢性心力衰竭患者心功能的评估价值[J]. 临床和实验医学杂志, 2018, 17(24): 2626-2629. doi: 10.3969/j.issn.1671-4695.2018.24.015
    [17]
    沈克锋, 江千里, 刘启发, 等. 慢性髓系白血病患者移植早期急性心衰事件的危险因素及临床分析[J]. 中国实验血液学杂志, 2015, 23(1): 178-182. https://www.cnki.com.cn/Article/CJFDTOTAL-XYSY201501038.htm
    [18]
    FUSE K, TANAKA T, SHIBASAKI Y, et al. Marker chromosome is a strong poor prognosis factor after allogeneic HSCT for adverse-risk AML patients[J]. Eur J Haematol, 2020, 105(5): 616-625. doi: 10.1111/ejh.13495
    [19]
    明茜, 肖毅. 异基因造血干细胞移植治疗慢性活动性EB病毒感染的研究进展[J]. 临床内科杂志, 2020, 37(7): 523-525. doi: 10.3969/j.issn.1001-9057.2020.07.020
    [20]
    陈冬, 裴仁治, 陆滢, 等. 自体造血干细胞移植治疗复发难治性外周T细胞淋巴瘤疗效及预后分析[J]. 中华全科医学, 2020, 18(1): 59-61. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202001017.htm
    [21]
    JARMOLI I N ' SKI T, MATKOWSKA-KOCJAN A, ROSA M, et al. SARS-CoV-2 viral clearance during bone marrow aplasia after allogeneic hematopoietic stem cell transplantation-a case report[J]. Pediatr Transplant, 2020. DOI: 10.1111/petr.13875.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (224) PDF downloads(6) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return